Partial
Needs Revision
Patient Risk:
Medium
Summary
Several pediatric dosing/age-related claims are not supported or conflict with the provided label (not established for <1 year; pediatric dosing table applies 1–16 years). Additional content about biosimilars is unsupported by the supplied label excerpts. Other statements are broadly consistent but are overgeneralized beyond label wording/duration specifics.
Category Scores
Accurate Statements
The optimal omeprazole dose for children with GERD may vary depending on weight, age, and individual response to treatment.
Supported partially: pediatric dosing is weight-based (Section 2.7) and clinical studies describe dose initiation/titration/maintenance in pediatric GERD (Section 14.6), but the label language provided does not explicitly support 'age' as a determinant in this general phrasing.
Omeprazole treatment for GERD in children usually lasts several weeks or months, depending on severity of symptoms and response.
Supported partially: label provides short-term 4–8 week treatment for pediatric erosive esophagitis and mentions additional 4–8 week courses and longer study maintenance context (Section 1.3, Section 14.6), but the claim generalizes wording ('severity of symptoms') beyond the provided label language.
In some cases, ongoing omeprazole treatment may be necessary to manage GERD symptoms in children.
Supported partially: label discusses additional 4–8 week courses upon recurrence and maintenance of healing concepts (Section 1.3, Section 14.6), but the claim is broader ('GERD symptoms') than the label-supported contexts shown in the excerpts.
Unsupported Statements
Biosimilar versions of omeprazole (such as Zyrova) may be available as alternatives to brand-name medication.
The provided label excerpts do not mention biosimilars, alternative brands, or 'Zyrova' (no support in supplied text).
Biosimilars of omeprazole have shown similar efficacy and safety profiles.
The provided label excerpts do not discuss biosimilars or provide comparative efficacy/safety statements for biosimilars (no support in supplied text).
Contradictions
Low
AI Statement
Omeprazole is FDA-approved for treating gastroesophageal reflux disease (GERD) in children six months of age and older.
Label Reference
Provided label pediatric dosing/clinical evidence applies to 1–16 years, and the label states safety/effectiveness for GERD have not been established for patients <1 year (Section 8.4). This conflicts with asserting approval for 6 months and older based on the supplied excerpts.
Low
AI Statement
Typical omeprazole dose for infants 1-11 months with GERD is 0.5-1.0 mg/kg once daily.
Label Reference
The label excerpt states safety and effectiveness for GERD in patients <1 year have not been established (Section 8.4). The provided pediatric dosing table/clinical studies in the excerpts start at age 1 (Section 2.7, Section 14.6), so this infant dosing claim is contradicted/unsupported by the supplied label excerpts.
Important Omissions
Dose ranges should reflect the labeled pediatric weight-based options (5 mg, 10 mg, 20 mg for ages 1–16 years) rather than stating only 10–20 mg once daily for all 1–16 year olds.
Importance:
Moderate
The label-provided short-term duration for pediatric erosive esophagitis is 4–8 weeks, with additional 4–8 week courses considered upon recurrence; the claim does not specify this label linkage/duration boundaries.
Importance:
Moderate
The label pediatric dosing table is weight-based; the claim about age-based optimization is not explicitly supported by the provided excerpts and could mislead without clarifying weight-based dosing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Conflicting/unsupported pediatric age and infant dosing claims (asserting treatment/typical dosing for <1 year) and omission of labeled pediatric weight-based dosing options could lead to inappropriate pediatric use if followed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Pediatric age qualifier and infant dosing are not supported by the provided label excerpts (<1 year safety/effectiveness not established), and biosimilar claims are unsupported. Pediatric dosing also omits the 5 mg weight band.
Suggested Improvement
Restrict pediatric indications/dosing to the label-supported age group (1–16 years in provided excerpts) and reflect weight-based dosing (5 mg for 5<10 kg; 10 mg for 10<20 kg; 20 mg for ≥20 kg). Remove biosimilar/brand-specific claims not present in the supplied label text and use the label language for treatment duration (4–8 weeks for erosive esophagitis, with additional 4–8 week courses considered upon recurrence).